These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9932082)

  • 1. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
    Van Cutsem E; Peeters M
    Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
    Mitry E; Ducreux M; Rougier P
    Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
    Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Irinotecan in combination for colon cancer].
    Ducreux M; Gil-Delgado M; André T; Ychou M; de Gramond A; Khayat D
    Bull Cancer; 1998 Dec; Spec No():43-6. PubMed ID: 9932084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical activity spectrum of irinotecan].
    Cottu PH; Extra JM; Lerebours F; Espie M; Marty M
    Bull Cancer; 1998 Dec; Spec No():21-5. PubMed ID: 9932080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
    Fuchs CS; Moore MR; Harker G; Villa L; Rinaldi D; Hecht JR
    J Clin Oncol; 2003 Mar; 21(5):807-14. PubMed ID: 12610178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Van Cutsem E; Blijham GH
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
    Rougier P; Van Cutsem E; Bajetta E; Niederle N; Possinger K; Labianca R; Navarro M; Morant R; Bleiberg H; Wils J; Awad L; Herait P; Jacques C
    Lancet; 1998 Oct; 352(9138):1407-12. PubMed ID: 9807986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
    Cunningham D; Pyrhönen S; James RD; Punt CJ; Hickish TF; Heikkila R; Johannesen TB; Starkhammar H; Topham CA; Awad L; Jacques C; Herait P
    Lancet; 1998 Oct; 352(9138):1413-8. PubMed ID: 9807987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
    Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
    Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
    Boige V; Raymond E; Armand JP
    Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
    Cunningham D; Glimelius B
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):6-12. PubMed ID: 10213009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
    Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
    J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA approves irinotecan as first-line therapy for colorectal cancer.
    Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457
    [No Abstract]   [Full Text] [Related]  

  • 15. US pivotal studies of irinotecan in colorectal carcinoma.
    Pitot HC
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):48-53. PubMed ID: 9726091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
    Ychou M; Raoul JL; Desseigne F; Borel C; Caroli-Bosc FX; Jacob JH; Seitz JF; Kramar A; Hua A; Lefebvre P; Couteau C; Merrouche Y
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):383-91. PubMed ID: 12439596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
    Rougier P; Bugat R
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.
    Gibbs P; Clingan PR; Ganju V; Strickland AH; Wong SS; Tebbutt NC; Underhill CR; Fox RM; Clavant SP; Leung J; Pho M; Brown TJ
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):153-63. PubMed ID: 20333384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
    Cunningham D
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):1-5. PubMed ID: 10213008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Wiseman LR; Markham A
    Drugs; 1996 Oct; 52(4):606-23. PubMed ID: 8891470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.